3Good Health and Well-being
SDG 3: Good Health and Well-being — Research Keywords
Research keywords that map publications to SDG 3 (Good Health and Well-being), from the Sustainability Research Mapping 2023 lists.
Golden list
Golden keywords
Keywords that identify this goal on their own. A superscript marks other goals that share the keyword.
antenatal care (anc)17cancer disparities10high hiv prevalence5hiv acquisition5hiv diagnosis5hiv knowledge5hiv prevention intervention5hiv risk behavior5hiv services5, 17hiv stigma5hiv/sti5hiv-exposed5hiv-positive men5hiv-related stigma5long-acting reversible5men living with hiv5mother-to-child transmission of hiv5pmtct5, 17pre-exposure prophylaxis (prep)5prevention of mother-to-child transmission5, 17women living with hiv5
Top 100
Top 100 keywords
The 100 most relevant keywords for this goal, by rank.
- 1allergy, asthma
- 2community-acquired pneumonia (cap)
- 3metastasis-free survival
- 4prostate cancer cell lines
- 5cancer quality of life
- 6cancer outcomes
- 7papillary thyroid carcinoma (ptc)
- 8stroke severity
- 9egfr-tki
- 10cancer resistance
- 11asthma exacerbations
- 12advanced rectal cancer
- 13type 2 diabetes (t2dm)
- 14type 1 diabetes mellitus (t1dm)
- 15overweight or obesity
- 16stroke outcome
- 17muscle-invasive bladder cancer
- 18hcc cell lines
- 19cardiovascular disease (cvd) risk
- 20diabetes prevention
- 21folfox
- 22hiv diagnosis
- 23response evaluation criteria in solid tumor
- 24mcf-7 breast cancer cells
- 25interstitial lung disease (ild)
- 26pathological complete response
- 27art initiation
- 28national comprehensive cancer network
- 29combination antiretroviral therapy
- 30prostate cancer risk
- 31european organization for research and treatment of cancer
- 32pc-3 cells
- 33xenograft tumors
- 34acute ischemic stroke (ais)
- 35mouse xenograft model
- 36breast cancer subtype
- 37stroke care
- 38response evaluation criteria in solid tumors
- 39cancer cell death
- 40obesity risk
- 41dengue virus (denv)
- 42egfr tyrosine kinase
- 43anti-cancer effects
- 44sustained virologic response
- 45persistent asthma
- 46european society for medical oncology
- 47national cancer database
- 48obesity and insulin resistance
- 49cancer resection
- 50objective response rate (orr)
- 51advanced non-small cell lung cancer (nsclc)
- 52cvd event
- 53large b cell lymphoma
- 54lung cancer screen
- 55highly pathogenic avian influenza
- 56lung cancer screening
- 57epithelial ovarian cancer (eoc)
- 58rectal cancer surgery
- 59nonsmall cell
- 60cancer development and progression
- 61sentinel lymph nodes
- 62kras mutations
- 63hepatitis e virus (hev)
- 64neoadjuvant chemotherapy
- 65diffuse large b cell
- 66non-small cell lung cancer patients
- 67multidrug-resistant tuberculosis
- 68locally advanced rectal cancer
- 69cancer cell invasion
- 70hiv viral load
- 71metastatic castration-resistant
- 72nonsmall cell lung
- 73malt lymphoma
- 74cancer survivorship
- 75advanced hepatocellular carcinoma
- 76her2+
- 77chronic hepatitis c virus (hcv)
- 78chemoradiation therapy
- 79suicide ideation
- 80cancer drug delivery
- 81advanced hcc
- 82hcv patients
- 83neoadjuvant chemoradiotherapy
- 84pharyngeal squamous cell carcinoma
- 85hereditary breast
- 86controlled asthma
- 87pathologic complete response
- 88ovarian cancer cell lines
- 89cancer gene therapy
- 90prostate cancer (pc)
- 91hiv-uninfected
- 92hepatitis c patients
- 93advanced pancreatic cancer
- 94cancer-specific mortality
- 95adults with type 2 diabetes
- 96carcinoma hepatocellular
- 97sentinel node biopsy
- 98metastatic castration-resistant prostate cancer
- 99hiv-1 subtype
- 100anti-her2
Top 1,000
Top 1,000 keywords
Rank, keyword and its metrics in Scopus.
1000 keywords shown
| Rank | Keyword | Papers in the SDG set | Papers in all of Scopus | tf-idf | % of Scopus |
|---|---|---|---|---|---|
| 1 | national institutes of health stroke scale score | 1,802 | 1,820 | 19.06 | 99% |
| 2 | international association for the study of lung cancer | 2,263 | 2,318 | 19.05 | 98% |
| 3 | stroke thrombectomy | 1,715 | 1,745 | 19.04 | 98% |
| 4 | functional assessment of cancer therapy | 2,793 | 2,864 | 19.04 | 98% |
| 5 | european prospective investigation into cancer | 1,617 | 1,643 | 19.04 | 98% |
| 6 | sustained virological response (svr) | 2,512 | 2,585 | 19.04 | 97% |
| 7 | alcohol use disorders identification test | 2,409 | 2,481 | 19.04 | 97% |
| 8 | diabetes mellitus, type 2 | 1,543 | 1,565 | 19.03 | 99% |
| 9 | breast cancer resistance protein | 2,388 | 2,468 | 19.03 | 97% |
| 10 | adolescents with type 1 diabetes | 2,576 | 2,665 | 19.03 | 97% |
| 11 | national cancer database | 3,669 | 3,725 | 19.02 | 98% |
| 12 | hiv/hcv | 2,128 | 2,205 | 19.02 | 97% |
| 13 | kaposi’s sarcoma-associated herpesvirus | 2,098 | 2,176 | 19.02 | 96% |
| 14 | barcelona clinic liver cancer | 1,775 | 1,830 | 19.02 | 97% |
| 15 | european prospective investigation into cancer and nutrition | 1,439 | 1,461 | 19.02 | 98% |
| 16 | distant metastasis-free survival | 2,283 | 2,374 | 19.02 | 96% |
| 17 | breast cancer resistance | 2,619 | 2,720 | 19.02 | 96% |
| 18 | oropharyngeal squamous cell carcinoma | 2,566 | 2,667 | 19.02 | 96% |
| 19 | mda-mb-231 breast cancer cells | 2,054 | 2,135 | 19.02 | 96% |
| 20 | metastatic renal cell carcinoma (mrcc) | 1,797 | 1,859 | 19.02 | 97% |
| 21 | european organisation for research and treatment of cancer | 1,831 | 1,896 | 19.02 | 97% |
| 22 | incident diabetes | 1,995 | 2,073 | 19.02 | 96% |
| 23 | high-risk prostate cancer | 1,867 | 1,936 | 19.02 | 96% |
| 24 | plasma hiv-1 rna | 1,437 | 1,463 | 19.02 | 98% |
| 25 | biochemical failure | 2,170 | 2,260 | 19.02 | 96% |
| 26 | metastatic colorectal cancer (mcrc) | 3,188 | 3,289 | 19.01 | 97% |
| 27 | pathologic complete response (pcr) | 1,647 | 1,698 | 19.01 | 97% |
| 28 | national institutes of health stroke scale (nihss) | 3,233 | 3,333 | 19.01 | 97% |
| 29 | chemoradiotherapy (crt) | 2,986 | 3,093 | 19.01 | 97% |
| 30 | national institute of health stroke scale | 1,833 | 1,902 | 19.01 | 96% |
| 31 | prostate-specific membrane antigen (psma) | 2,024 | 2,108 | 19.01 | 96% |
| 32 | metastatic castration-resistant prostate cancer (mcrpc) | 1,633 | 1,685 | 19.01 | 97% |
| 33 | pandemic influenza a | 2,100 | 2,191 | 19.01 | 96% |
| 34 | colorectal cancer (crc) screening | 1,698 | 1,757 | 19.01 | 97% |
| 35 | mda-mb-231 breast cancer cell | 2,626 | 2,739 | 19.01 | 96% |
| 36 | chronic hepatitis c (chc) | 2,512 | 2,624 | 19.01 | 96% |
| 37 | metastatic crc | 1,922 | 2,004 | 19.01 | 96% |
| 38 | health services accessibility | 1,929 | 2,012 | 19.01 | 96% |
| 39 | non–small cell lung | 1,979 | 2,066 | 19.01 | 96% |
| 40 | pandemic h1n1 | 1,809 | 1,882 | 19.01 | 96% |
| 41 | hbv genotype | 2,169 | 2,269 | 19.01 | 96% |
| 42 | non–small cell | 2,002 | 2,093 | 19.01 | 96% |
| 43 | cancer and nutrition | 1,556 | 1,605 | 19.01 | 97% |
| 44 | sentinel lymph node biopsy (slnb) | 2,140 | 2,241 | 19 | 95% |
| 45 | disease-specific survival (dss) | 2,757 | 2,879 | 19 | 96% |
| 46 | 2009 pandemic | 2,024 | 2,118 | 19 | 96% |
| 47 | substance-related disorder | 2,262 | 2,371 | 19 | 95% |
| 48 | asthma control test | 1,750 | 1,821 | 19 | 96% |
| 49 | hcc recurrence | 1,900 | 1,985 | 19 | 96% |
| 50 | international prognostic index | 2,930 | 3,054 | 19 | 96% |
| 51 | substance-related disorders | 2,106 | 2,207 | 19 | 95% |
| 52 | mcrpc | 2,717 | 2,841 | 19 | 96% |
| 53 | non–small cell lung cancer | 1,873 | 1,957 | 19 | 96% |
| 54 | a549 lung cancer | 1,800 | 1,878 | 19 | 96% |
| 55 | tumor-node-metastasis | 2,424 | 2,543 | 19 | 95% |
| 56 | her2 status | 2,540 | 2,663 | 19 | 95% |
| 57 | sln biopsy | 1,471 | 1,513 | 19 | 97% |
| 58 | stroke center | 2,593 | 2,718 | 19 | 95% |
| 59 | global initiative for chronic obstructive lung disease | 1,696 | 1,766 | 19 | 96% |
| 60 | hcv treatment | 3,115 | 3,245 | 19 | 96% |
| 61 | non-muscle-invasive | 1,833 | 1,918 | 19 | 96% |
| 62 | advanced hepatocellular carcinoma (hcc) | 1,781 | 1,861 | 19 | 96% |
| 63 | hcv genotype 1 | 2,740 | 2,873 | 19 | 95% |
| 64 | neuroblastoma sh-sy5y cell | 1,829 | 1,915 | 19 | 96% |
| 65 | nsclcs | 2,218 | 2,334 | 19 | 95% |
| 66 | hiv-uninfected | 3,292 | 3,421 | 19 | 96% |
| 67 | cancer cell apoptosis | 2,425 | 2,552 | 19 | 95% |
| 68 | hiv-1 subtype | 3,245 | 3,376 | 19 | 96% |
| 69 | peripheral artery disease (pad) | 2,802 | 2,938 | 19 | 95% |
| 70 | pdm09 | 2,289 | 2,410 | 19 | 95% |
| 71 | adults with type 2 diabetes | 3,260 | 3,391 | 19 | 96% |
| 72 | metastatic breast cancer (mbc) | 2,617 | 2,751 | 18.99 | 95% |
| 73 | epidermal growth factor receptor (egfr) mutation | 2,137 | 2,250 | 18.99 | 95% |
| 74 | cancer-specific mortality | 3,264 | 3,396 | 18.99 | 96% |
| 75 | papillary thyroid cancer (ptc) | 2,024 | 2,129 | 18.99 | 95% |
| 76 | weekly paclitaxel | 1,585 | 1,647 | 18.99 | 96% |
| 77 | neuroblastoma sh-sy5y | 2,012 | 2,117 | 18.99 | 95% |
| 78 | egfr tyrosine kinase inhibitors | 1,922 | 2,020 | 18.99 | 95% |
| 79 | shiga toxin-producing escherichia coli | 2,557 | 2,692 | 18.99 | 95% |
| 80 | uncontrolled asthma | 1,899 | 1,996 | 18.99 | 95% |
| 81 | prostate cancer radiotherapy | 1,717 | 1,796 | 18.99 | 96% |
| 82 | diabetes status | 2,912 | 3,055 | 18.99 | 95% |
| 83 | opscc | 1,469 | 1,520 | 18.99 | 97% |
| 84 | european society for medical oncology | 3,694 | 3,816 | 18.99 | 97% |
| 85 | neuroblastoma sh-sy5y cells | 1,604 | 1,673 | 18.99 | 96% |
| 86 | baseline hba1c | 1,663 | 1,739 | 18.99 | 96% |
| 87 | asthma outcome | 1,476 | 1,529 | 18.99 | 97% |
| 88 | a549 lung cancer cell | 1,611 | 1,681 | 18.99 | 96% |
| 89 | neoadjuvant chemoradiation | 2,054 | 2,168 | 18.99 | 95% |
| 90 | substance use treatment | 1,991 | 2,100 | 18.99 | 95% |
| 91 | chronic hepatitis c virus (hcv) infection | 2,586 | 2,729 | 18.99 | 95% |
| 92 | cancer-related fatigue | 1,715 | 1,798 | 18.99 | 95% |
| 93 | hbv dna level | 2,409 | 2,546 | 18.99 | 95% |
| 94 | stroke thrombolysis | 1,490 | 1,546 | 18.99 | 96% |
| 95 | head and neck cancer (hnc) | 3,078 | 3,226 | 18.99 | 95% |
| 96 | nmibc | 2,285 | 2,416 | 18.99 | 95% |
| 97 | acute ischemic stroke patients | 2,766 | 2,914 | 18.99 | 95% |
| 98 | diabetes medication | 2,084 | 2,202 | 18.99 | 95% |
| 99 | hiv-rna | 1,457 | 1,509 | 18.99 | 97% |
| 100 | anthracycline-based | 2,096 | 2,215 | 18.99 | 95% |
| 101 | a(h1n1)pdm09 | 1,391 | 1,434 | 18.99 | 97% |
| 102 | follicular lymphoma (fl) | 2,162 | 2,286 | 18.99 | 95% |
| 103 | neoadjuvant chemotherapy (nac) | 3,008 | 3,158 | 18.99 | 95% |
| 104 | anaplastic lymphoma kinase (alk) | 3,238 | 3,385 | 18.99 | 96% |
| 105 | crc risk | 2,166 | 2,291 | 18.99 | 95% |
| 106 | interferon and ribavirin | 2,755 | 2,905 | 18.99 | 95% |
| 107 | trail-induced apoptosis | 1,770 | 1,861 | 18.99 | 95% |
| 108 | cancer stem-like cells | 1,889 | 1,992 | 18.99 | 95% |
| 109 | tuberculin skin test (tst) | 1,797 | 1,891 | 18.99 | 95% |
| 110 | cancer stem-like | 2,353 | 2,490 | 18.99 | 94% |
| 111 | cancer stem-like cell | 2,098 | 2,219 | 18.99 | 95% |
| 112 | clear cell rcc | 1,758 | 1,848 | 18.99 | 95% |
| 113 | childhood cancer survivors | 2,471 | 2,614 | 18.99 | 95% |
| 114 | exposure to pm2.5 | 2,051 | 2,169 | 18.98 | 95% |
| 115 | egfr tk | 1,758 | 1,849 | 18.98 | 95% |
| 116 | asthma phenotype | 1,709 | 1,795 | 18.98 | 95% |
| 117 | slnb | 2,728 | 2,881 | 18.98 | 95% |
| 118 | marginal zone lymphoma | 2,415 | 2,558 | 18.98 | 94% |
| 119 | msi-h | 2,347 | 2,487 | 18.98 | 94% |
| 120 | pediatric obesity | 2,384 | 2,526 | 18.98 | 94% |
| 121 | mantle cell lymphoma (mcl) | 2,344 | 2,484 | 18.98 | 94% |
| 122 | differentiated thyroid cancer (dtc) | 1,690 | 1,775 | 18.98 | 95% |
| 123 | risk of ischemic stroke | 2,533 | 2,682 | 18.98 | 94% |
| 124 | sustained virologic response (svr) | 1,491 | 1,552 | 18.98 | 96% |
| 125 | metastatic nsclc | 1,908 | 2,017 | 18.98 | 95% |
| 126 | concurrent chemoradiation | 2,105 | 2,231 | 18.98 | 94% |
| 127 | egfr tki | 1,645 | 1,726 | 18.98 | 95% |
| 128 | shiga toxin-producing escherichia coli (stec) | 1,619 | 1,697 | 18.98 | 95% |
| 129 | stroke outcomes | 1,640 | 1,721 | 18.98 | 95% |
| 130 | and end results database | 2,312 | 2,453 | 18.98 | 94% |
| 131 | ca-mrsa | 1,850 | 1,955 | 18.98 | 95% |
| 132 | sustained virologic response | 3,706 | 3,845 | 18.98 | 96% |
| 133 | metastatic castration-resistant prostate cancer | 3,249 | 3,407 | 18.98 | 95% |
| 134 | health services access | 2,126 | 2,256 | 18.98 | 94% |
| 135 | asthma outcomes | 1,317 | 1,355 | 18.98 | 97% |
| 136 | latent tuberculosis infection (ltbi) | 1,535 | 1,604 | 18.98 | 96% |
| 137 | pharyngeal squamous cell carcinoma | 3,342 | 3,499 | 18.98 | 96% |
| 138 | hiv-infected adults | 2,734 | 2,894 | 18.98 | 94% |
| 139 | ckd stages | 2,179 | 2,314 | 18.98 | 94% |
| 140 | egfr-tkis | 2,454 | 2,605 | 18.98 | 94% |
| 141 | surveillance, epidemiology, and end results database | 1,747 | 1,843 | 18.98 | 95% |
| 142 | cvd events | 3,143 | 3,306 | 18.98 | 95% |
| 143 | hcv therapy | 1,373 | 1,421 | 18.98 | 97% |
| 144 | end results database | 2,338 | 2,485 | 18.98 | 94% |
| 145 | breast cancer mcf-7 | 2,195 | 2,333 | 18.98 | 94% |
| 146 | national cancer data base | 1,266 | 1,298 | 18.98 | 98% |
| 147 | direct-acting antivirals | 3,189 | 3,353 | 18.98 | 95% |
| 148 | national comprehensive cancer network | 3,878 | 4,013 | 18.98 | 97% |
| 149 | chronic thromboembolic pulmonary hypertension (cteph) | 1,540 | 1,612 | 18.98 | 96% |
| 150 | milan criteria | 1,609 | 1,690 | 18.98 | 95% |
| 151 | crc screening | 3,214 | 3,378 | 18.98 | 95% |
| 152 | l858r | 2,307 | 2,453 | 18.98 | 94% |
| 153 | prostate cancer diagnosis | 1,881 | 1,993 | 18.98 | 94% |
| 154 | hiv/sti | 1,494 | 1,560 | 18.98 | 96% |
| 155 | chb patients | 2,869 | 3,035 | 18.98 | 95% |
| 156 | anticancer efficacy | 3,155 | 3,321 | 18.98 | 95% |
| 157 | childhood cancer survivor | 2,764 | 2,929 | 18.98 | 94% |
| 158 | hiv acquisition | 2,348 | 2,498 | 18.98 | 94% |
| 159 | prevention of mother-to-child transmission | 1,977 | 2,100 | 18.98 | 94% |
| 160 | children with type 1 diabetes | 2,625 | 2,788 | 18.97 | 94% |
| 161 | significant prostate cancer | 1,668 | 1,758 | 18.97 | 95% |
| 162 | cancer targeted | 2,467 | 2,624 | 18.97 | 94% |
| 163 | latent tuberculosis infection | 3,184 | 3,352 | 18.97 | 95% |
| 164 | hiv prevention intervention | 1,802 | 1,908 | 18.97 | 94% |
| 165 | kaposi’s sarcoma-associated herpesvirus (kshv) | 1,323 | 1,366 | 18.97 | 97% |
| 166 | locally advanced rectal cancer | 3,462 | 3,624 | 18.97 | 96% |
| 167 | genotype 1b | 2,162 | 2,302 | 18.97 | 94% |
| 168 | stroke registry | 2,004 | 2,131 | 18.97 | 94% |
| 169 | sentinel nodes | 2,037 | 2,167 | 18.97 | 94% |
| 170 | peritoneal cancer | 2,010 | 2,138 | 18.97 | 94% |
| 171 | metastatic castration-resistant | 3,419 | 3,584 | 18.97 | 95% |
| 172 | escherichia coli (stec) | 2,331 | 2,483 | 18.97 | 94% |
| 173 | her2 expression | 2,066 | 2,199 | 18.97 | 94% |
| 174 | transarterial chemoembolization (tace) | 2,411 | 2,568 | 18.97 | 94% |
| 175 | hiv-exposed | 1,766 | 1,870 | 18.97 | 94% |
| 176 | improving global outcomes | 2,092 | 2,228 | 18.97 | 94% |
| 177 | hiv-1 subtypes | 1,406 | 1,463 | 18.97 | 96% |
| 178 | lymph node ratio | 1,546 | 1,623 | 18.97 | 95% |
| 179 | asthma diagnosis | 1,744 | 1,846 | 18.97 | 94% |
| 180 | castration-resistant prostate cancer (crpc) | 2,451 | 2,612 | 18.97 | 94% |
| 181 | hiv-1 integrase | 1,825 | 1,937 | 18.97 | 94% |
| 182 | brca1/2 mutation | 2,130 | 2,271 | 18.97 | 94% |
| 183 | end-stage kidney disease (eskd) | 1,566 | 1,647 | 18.97 | 95% |
| 184 | obstructive cad | 1,536 | 1,613 | 18.97 | 95% |
| 185 | prostate cancer (pc) | 3,303 | 3,477 | 18.97 | 95% |
| 186 | b-cell lymphoma-2 | 1,677 | 1,773 | 18.97 | 95% |
| 187 | folfiri | 2,956 | 3,134 | 18.97 | 94% |
| 188 | diabetic kidney disease (dkd) | 1,993 | 2,124 | 18.97 | 94% |
| 189 | mucosa-associated lymphoid tissue lymphoma | 1,571 | 1,654 | 18.97 | 95% |
| 190 | cancer pain relief | 2,164 | 2,310 | 18.97 | 94% |
| 191 | chronic hepatitis c patients | 2,257 | 2,410 | 18.97 | 94% |
| 192 | colorectal cancer risk | 2,801 | 2,978 | 18.97 | 94% |
| 193 | combination antiretroviral therapy (cart) | 1,810 | 1,923 | 18.97 | 94% |
| 194 | human prostate cancer cells | 2,923 | 3,102 | 18.97 | 94% |
| 195 | pathological complete response (pcr) | 1,893 | 2,015 | 18.97 | 94% |
| 196 | tki treatment | 1,674 | 1,771 | 18.97 | 95% |
| 197 | ln metastasis | 2,703 | 2,878 | 18.97 | 94% |
| 198 | pm2.5 exposure | 2,904 | 3,083 | 18.97 | 94% |
| 199 | incident stroke | 1,358 | 1,411 | 18.97 | 96% |
| 200 | cryptogenic stroke | 1,880 | 2,001 | 18.97 | 94% |
| 201 | recurrent ovarian cancer | 2,011 | 2,145 | 18.97 | 94% |
| 202 | crc cell lines | 2,461 | 2,627 | 18.97 | 94% |
| 203 | sentinel lymph node (sln) | 3,107 | 3,287 | 18.97 | 95% |
| 204 | sustained viral response | 1,389 | 1,447 | 18.97 | 96% |
| 205 | hodgkin lymphoma (hl) | 2,301 | 2,458 | 18.97 | 94% |
| 206 | adjuvant chemoradiation | 2,842 | 3,021 | 18.97 | 94% |
| 207 | tki therapy | 1,607 | 1,696 | 18.97 | 95% |
| 208 | hormone receptor-positive | 3,088 | 3,269 | 18.97 | 94% |
| 209 | hbv dna levels | 1,691 | 1,791 | 18.97 | 94% |
| 210 | breast cancer mcf-7 cell | 1,649 | 1,744 | 18.97 | 95% |
| 211 | new-onset diabetes | 2,030 | 2,167 | 18.97 | 94% |
| 212 | incidence of type 2 diabetes | 1,719 | 1,823 | 18.97 | 94% |
| 213 | anti-obesity effect | 2,097 | 2,240 | 18.97 | 94% |
| 214 | nonsmall cell lung cancer (nsclc) | 1,464 | 1,534 | 18.97 | 95% |
| 215 | peg-ifn | 2,605 | 2,779 | 18.97 | 94% |
| 216 | chronic hepatitis c virus (hcv) | 3,381 | 3,559 | 18.97 | 95% |
| 217 | p[8] | 1,249 | 1,286 | 18.97 | 97% |
| 218 | programmed death-ligand 1 (pd-l1) | 2,057 | 2,197 | 18.97 | 94% |
| 219 | chronic thromboembolic pulmonary hypertension | 2,518 | 2,689 | 18.97 | 94% |
| 220 | metastatic rcc | 2,175 | 2,325 | 18.97 | 94% |
| 221 | urothelial carcinoma (uc) | 1,285 | 1,328 | 18.97 | 97% |
| 222 | human colorectal cancer cell | 2,214 | 2,367 | 18.97 | 94% |
| 223 | resistant breast cancer | 2,186 | 2,337 | 18.97 | 94% |
| 224 | cancer-related genes | 2,525 | 2,697 | 18.97 | 94% |
| 225 | h5n1 virus | 2,317 | 2,478 | 18.97 | 94% |
| 226 | hiv coinfection | 1,591 | 1,680 | 18.97 | 95% |
| 227 | gastric cancer cell lines | 2,653 | 2,831 | 18.97 | 94% |
| 228 | thrombolysis in cerebral infarction | 1,219 | 1,252 | 18.97 | 97% |
| 229 | atherosclerotic cardiovascular disease (ascvd) | 1,976 | 2,110 | 18.97 | 94% |
| 230 | androgen deprivation therapy (adt) | 2,986 | 3,171 | 18.97 | 94% |
| 231 | flt3-itd | 1,866 | 1,989 | 18.96 | 94% |
| 232 | type 2 diabetes mellitus (dm) | 2,632 | 2,810 | 18.96 | 94% |
| 233 | virologic failure | 1,639 | 1,735 | 18.96 | 94% |
| 234 | cancer xenograft model | 1,392 | 1,453 | 18.96 | 96% |
| 235 | apoptosis of cancer cells | 1,425 | 1,491 | 18.96 | 96% |
| 236 | 2009 h1n1 | 1,773 | 1,886 | 18.96 | 94% |
| 237 | substance use disorder (sud) | 2,249 | 2,407 | 18.96 | 93% |
| 238 | asthma model | 2,038 | 2,179 | 18.96 | 94% |
| 239 | large vessel occlusion | 2,921 | 3,107 | 18.96 | 94% |
| 240 | anti-cancer properties | 2,069 | 2,213 | 18.96 | 93% |
| 241 | brca2 mutation | 2,996 | 3,183 | 18.96 | 94% |
| 242 | advanced non-small-cell lung cancer (nsclc) | 1,565 | 1,652 | 18.96 | 95% |
| 243 | hnscc patients | 2,443 | 2,614 | 18.96 | 93% |
| 244 | progression of chronic kidney disease | 1,801 | 1,918 | 18.96 | 94% |
| 245 | integrase inhibitor | 2,420 | 2,590 | 18.96 | 93% |
| 246 | chronic thromboembolic pulmonary | 2,537 | 2,713 | 18.96 | 94% |
| 247 | plasma hiv rna | 1,278 | 1,322 | 18.96 | 97% |
| 248 | her2-positive breast cancer | 2,898 | 3,085 | 18.96 | 94% |
| 249 | sentinel node biopsy | 3,250 | 3,437 | 18.96 | 95% |
| 250 | stroke subtypes | 1,895 | 2,023 | 18.96 | 94% |
| 251 | her2-negative | 3,168 | 3,356 | 18.96 | 94% |
| 252 | endometrial cancer (ec) | 2,464 | 2,637 | 18.96 | 93% |
| 253 | ln metastases | 1,496 | 1,574 | 18.96 | 95% |
| 254 | head-and-neck cancer | 1,325 | 1,377 | 18.96 | 96% |
| 255 | diabetes-related complication | 1,703 | 1,809 | 18.96 | 94% |
| 256 | stroke recurrence | 2,144 | 2,296 | 18.96 | 93% |
| 257 | her2 positive | 1,826 | 1,947 | 18.96 | 94% |
| 258 | diabetes self-management | 3,170 | 3,359 | 18.96 | 94% |
| 259 | muscle invasive bladder cancer | 2,676 | 2,859 | 18.96 | 94% |
| 260 | hepatitis c virus genotype | 1,897 | 2,026 | 18.96 | 94% |
| 261 | t790m | 2,812 | 2,999 | 18.96 | 94% |
| 262 | human neuroblastoma sh-sy5y | 1,512 | 1,593 | 18.96 | 95% |
| 263 | cancer cell survival | 2,654 | 2,837 | 18.96 | 94% |
| 264 | cancer-specific survival (css) | 3,176 | 3,366 | 18.96 | 94% |
| 265 | targeted cancer therapy | 2,119 | 2,270 | 18.96 | 93% |
| 266 | anticancer drug delivery | 1,663 | 1,765 | 18.96 | 94% |
| 267 | brca1 mutation | 2,154 | 2,308 | 18.96 | 93% |
| 268 | antiretroviral treatment (art) | 2,175 | 2,331 | 18.96 | 93% |
| 269 | women living with hiv | 2,369 | 2,539 | 18.96 | 93% |
| 270 | obesity status | 1,771 | 1,887 | 18.96 | 94% |
| 271 | h5n1 influenza | 1,489 | 1,568 | 18.96 | 95% |
| 272 | biochemical recurrence (bcr) | 1,388 | 1,452 | 18.96 | 96% |
| 273 | non-small cell lung cancer cells | 2,050 | 2,197 | 18.96 | 93% |
| 274 | alk-positive | 1,679 | 1,785 | 18.96 | 94% |
| 275 | co-infected patients | 1,905 | 2,038 | 18.96 | 93% |
| 276 | upper tract urothelial carcinoma | 1,462 | 1,538 | 18.96 | 95% |
| 277 | international study of asthma and allergies in childhood | 1,132 | 1,154 | 18.96 | 98% |
| 278 | metabolic tumor volume | 1,558 | 1,648 | 18.96 | 95% |
| 279 | cancer detection rate | 2,179 | 2,338 | 18.96 | 93% |
| 280 | diabetes-related complications | 1,630 | 1,730 | 18.96 | 94% |
| 281 | american joint committee on cancer (ajcc) | 2,107 | 2,260 | 18.96 | 93% |
| 282 | her2 overexpression | 1,421 | 1,491 | 18.96 | 95% |
| 283 | diabetes model | 1,762 | 1,879 | 18.96 | 94% |
| 284 | nucleos(t)ide analog | 1,786 | 1,906 | 18.96 | 94% |
| 285 | transcatheter arterial chemoembolization (tace) | 1,873 | 2,003 | 18.96 | 94% |
| 286 | cancer inflammation | 1,728 | 1,841 | 18.96 | 94% |
| 287 | pathologic complete response | 3,332 | 3,525 | 18.96 | 95% |
| 288 | hcc treatment | 1,964 | 2,104 | 18.96 | 93% |
| 289 | multidrug-resistant tuberculosis (mdr-tb) | 1,478 | 1,557 | 18.96 | 95% |
| 290 | obesity type | 2,300 | 2,469 | 18.96 | 93% |
| 291 | prostate cancer treatment | 2,941 | 3,136 | 18.96 | 94% |
| 292 | non-muscle-invasive bladder cancer | 1,392 | 1,458 | 18.96 | 95% |
| 293 | b-cell non-hodgkin lymphoma | 1,538 | 1,626 | 18.96 | 95% |
| 294 | xenograft tumor growth | 1,509 | 1,593 | 18.96 | 95% |
| 295 | chronic hepatitis b patients | 2,592 | 2,778 | 18.96 | 93% |
| 296 | visceral obesity | 2,687 | 2,877 | 18.96 | 93% |
| 297 | people living with hiv (plwh) | 2,171 | 2,331 | 18.96 | 93% |
| 298 | suicide gene | 2,460 | 2,640 | 18.96 | 93% |
| 299 | hcc development | 2,912 | 3,108 | 18.96 | 94% |
| 300 | breast cancer model | 2,595 | 2,782 | 18.96 | 93% |
| 301 | treatment of hepatitis c | 2,050 | 2,200 | 18.96 | 93% |
| 302 | egfr tyrosine kinase inhibitor | 3,094 | 3,292 | 18.96 | 94% |
| 303 | hnscc cells | 1,293 | 1,344 | 18.96 | 96% |
| 304 | eastern cooperative oncology group performance status | 3,208 | 3,406 | 18.96 | 94% |
| 305 | sh-sy5y neuroblastoma | 1,886 | 2,020 | 18.96 | 93% |
| 306 | cancer history | 2,094 | 2,249 | 18.96 | 93% |
| 307 | oscc cells | 1,685 | 1,795 | 18.96 | 94% |
| 308 | stroke subtype | 2,970 | 3,169 | 18.96 | 94% |
| 309 | brca mutation | 2,700 | 2,893 | 18.96 | 93% |
| 310 | resistant cancer cells | 2,025 | 2,174 | 18.96 | 93% |
| 311 | prostate-specific membrane | 3,065 | 3,265 | 18.96 | 94% |
| 312 | prostate-specific membrane antigen | 3,050 | 3,250 | 18.96 | 94% |
| 313 | breast cancer mcf-7 cells | 1,391 | 1,459 | 18.96 | 95% |
| 314 | svr12 | 1,268 | 1,316 | 18.96 | 96% |
| 315 | brca2 mutations | 1,679 | 1,789 | 18.96 | 94% |
| 316 | tnbc cells | 2,372 | 2,550 | 18.96 | 93% |
| 317 | anticancer mechanism | 1,554 | 1,647 | 18.96 | 94% |
| 318 | nab-paclitaxel | 1,919 | 2,058 | 18.96 | 93% |
| 319 | overweight, obesity | 1,779 | 1,902 | 18.96 | 94% |
| 320 | hba 1c | 2,144 | 2,305 | 18.96 | 93% |
| 321 | metastatic setting | 1,993 | 2,140 | 18.96 | 93% |
| 322 | survivorship care | 1,706 | 1,820 | 18.96 | 94% |
| 323 | hiv rna level | 1,253 | 1,299 | 18.96 | 96% |
| 324 | cardiovascular disease (cvd) risk factors | 1,405 | 1,476 | 18.96 | 95% |
| 325 | allergy, asthma | 4,618 | 4,736 | 18.95 | 98% |
| 326 | anticancer therapeutic | 2,791 | 2,989 | 18.95 | 93% |
| 327 | ischemic stroke (is) | 2,439 | 2,622 | 18.95 | 93% |
| 328 | human neuroblastoma sh-sy5y cell | 1,404 | 1,475 | 18.95 | 95% |
| 329 | diabetes technology | 1,695 | 1,808 | 18.95 | 94% |
| 330 | nsclc cell lines | 2,714 | 2,910 | 18.95 | 93% |
| 331 | effusion lymphoma | 1,474 | 1,556 | 18.95 | 95% |
| 332 | chronic kidney disease epidemiology collaboration | 1,268 | 1,317 | 18.95 | 96% |
| 333 | lung cancer surgery | 1,899 | 2,037 | 18.95 | 93% |
| 334 | denv-2 | 1,453 | 1,532 | 18.95 | 95% |
| 335 | incident cvd | 1,279 | 1,330 | 18.95 | 96% |
| 336 | cvd event | 3,627 | 3,820 | 18.95 | 95% |
| 337 | acute ischaemic stroke | 2,405 | 2,587 | 18.95 | 93% |
| 338 | prevalence of type 2 diabetes | 2,454 | 2,639 | 18.95 | 93% |
| 339 | cteph | 1,784 | 1,909 | 18.95 | 93% |
| 340 | oligometastatic | 2,283 | 2,457 | 18.95 | 93% |
| 341 | virological failure | 2,123 | 2,284 | 18.95 | 93% |
| 342 | breast cancer susceptibility | 2,629 | 2,823 | 18.95 | 93% |
| 343 | t790m mutation | 1,418 | 1,492 | 18.95 | 95% |
| 344 | glucagon-like peptide-1 receptor agonist | 2,253 | 2,425 | 18.95 | 93% |
| 345 | large b-cell lymphomas | 1,514 | 1,603 | 18.95 | 94% |
| 346 | hepatitis c treatment | 1,329 | 1,389 | 18.95 | 96% |
| 347 | pca cells | 2,566 | 2,758 | 18.95 | 93% |
| 348 | disease control rate (dcr) | 2,115 | 2,276 | 18.95 | 93% |
| 349 | second-line chemotherapy | 2,613 | 2,808 | 18.95 | 93% |
| 350 | linkage to care | 1,635 | 1,742 | 18.95 | 94% |
| 351 | a549 lung cancer cells | 1,242 | 1,288 | 18.95 | 96% |
| 352 | controlled asthma | 3,334 | 3,539 | 18.95 | 94% |
| 353 | prostate cancer progression | 3,111 | 3,318 | 18.95 | 94% |
| 354 | locally advanced cervical cancer | 1,768 | 1,893 | 18.95 | 93% |
| 355 | nucleos(t)ide | 2,132 | 2,296 | 18.95 | 93% |
| 356 | tumor necrosis factor-related apoptosis-inducing ligand (trail) | 1,789 | 1,917 | 18.95 | 93% |
| 357 | persistent asthma | 3,700 | 3,895 | 18.95 | 95% |
| 358 | symptomatic intracranial hemorrhage | 1,578 | 1,678 | 18.95 | 94% |
| 359 | men living with hiv | 2,915 | 3,121 | 18.95 | 93% |
| 360 | hiv stigma | 1,418 | 1,494 | 18.95 | 95% |
| 361 | concurrent chemoradiotherapy (ccrt) | 1,360 | 1,427 | 18.95 | 95% |
| 362 | advanced hcc | 3,355 | 3,562 | 18.95 | 94% |
| 363 | international diabetes federation | 2,811 | 3,016 | 18.95 | 93% |
| 364 | b-cell lymphoma 2 | 2,713 | 2,915 | 18.95 | 93% |
| 365 | stroke therapy | 2,228 | 2,402 | 18.95 | 93% |
| 366 | pancreatic cancer cell lines | 2,787 | 2,992 | 18.95 | 93% |
| 367 | tumor necrosis factor-related apoptosis-inducing ligand | 2,467 | 2,658 | 18.95 | 93% |
| 368 | cancer-related gene | 2,966 | 3,175 | 18.95 | 93% |
| 369 | curative-intent | 1,698 | 1,816 | 18.95 | 94% |
| 370 | microvascular invasion | 1,675 | 1,790 | 18.95 | 94% |
| 371 | response to neoadjuvant chemotherapy | 1,973 | 2,124 | 18.95 | 93% |
| 372 | breast cancer resistance protein (bcrp) | 1,186 | 1,224 | 18.95 | 97% |
| 373 | cancer stem cell (csc) | 1,891 | 2,033 | 18.95 | 93% |
| 374 | carcinoma, hepatocellular | 1,214 | 1,257 | 18.95 | 97% |
| 375 | mpmri | 1,873 | 2,013 | 18.95 | 93% |
| 376 | nonsmall cell lung cancer | 2,925 | 3,134 | 18.95 | 93% |
| 377 | bladder cancer (bc) | 1,934 | 2,081 | 18.95 | 93% |
| 378 | diffuse large b cell lymphoma | 3,232 | 3,443 | 18.95 | 94% |
| 379 | ventilator-associated pneumonia (vap) | 2,944 | 3,154 | 18.95 | 93% |
| 380 | hormone-refractory | 1,938 | 2,086 | 18.95 | 93% |
| 381 | ckd progression | 1,917 | 2,063 | 18.95 | 93% |
| 382 | hepatocellular carcinoma (hcc) cells | 1,356 | 1,424 | 18.95 | 95% |
| 383 | gemcitabine (gem) | 1,474 | 1,561 | 18.95 | 94% |
| 384 | denv infection | 1,600 | 1,706 | 18.95 | 94% |
| 385 | cancer mechanism | 2,792 | 3,000 | 18.95 | 93% |
| 386 | atherosclerosis cardiovascular disease | 2,690 | 2,895 | 18.95 | 93% |
| 387 | persons living with hiv | 2,263 | 2,443 | 18.95 | 93% |
| 388 | hmlh1 | 1,728 | 1,852 | 18.95 | 93% |
| 389 | ncdb | 1,638 | 1,750 | 18.95 | 94% |
| 390 | preoperative chemoradiotherapy | 1,638 | 1,750 | 18.95 | 94% |
| 391 | neoplasm staging | 1,749 | 1,876 | 18.95 | 93% |
| 392 | cancer cost | 1,702 | 1,823 | 18.95 | 93% |
| 393 | incident type 2 diabetes | 1,166 | 1,202 | 18.95 | 97% |
| 394 | testis antigen | 1,636 | 1,748 | 18.95 | 94% |
| 395 | b16f10 melanoma | 1,826 | 1,963 | 18.95 | 93% |
| 396 | seasonal influenza vaccine | 1,552 | 1,652 | 18.95 | 94% |
| 397 | prostate cancer detection | 1,937 | 2,087 | 18.95 | 93% |
| 398 | hiv co-infection | 2,134 | 2,304 | 18.95 | 93% |
| 399 | merkel cell carcinoma (mcc) | 1,523 | 1,619 | 18.95 | 94% |
| 400 | sh-sy5y neuroblastoma cell | 1,751 | 1,879 | 18.95 | 93% |
| 401 | brca1 or brca2 | 1,646 | 1,760 | 18.95 | 94% |
| 402 | primary effusion lymphoma | 1,432 | 1,514 | 18.95 | 95% |
| 403 | esophageal cancer (ec) | 1,688 | 1,808 | 18.95 | 93% |
| 404 | human colorectal cancer cells | 1,400 | 1,477 | 18.95 | 95% |
| 405 | neoadjuvant chemoradiotherapy | 3,352 | 3,567 | 18.95 | 94% |
| 406 | cardiovascular disease (cvd) risk | 3,968 | 4,160 | 18.95 | 95% |
| 407 | epidermal growth factor receptor tyrosine kinase inhibitor | 1,578 | 1,683 | 18.95 | 94% |
| 408 | pmtct | 2,047 | 2,210 | 18.95 | 93% |
| 409 | lung cancer treatment | 2,637 | 2,843 | 18.95 | 93% |
| 410 | epidermal growth factor receptor-2 | 1,576 | 1,681 | 18.95 | 94% |
| 411 | extrathyroidal extension | 1,377 | 1,451 | 18.95 | 95% |
| 412 | primary effusion | 1,457 | 1,544 | 18.95 | 94% |
| 413 | hiv-related stigma | 1,230 | 1,279 | 18.95 | 96% |
| 414 | human cervical cancer cell | 1,768 | 1,900 | 18.95 | 93% |
| 415 | lung cancer a549 | 1,442 | 1,527 | 18.95 | 94% |
| 416 | art adherence | 1,864 | 2,008 | 18.95 | 93% |
| 417 | gleason scores | 1,749 | 1,879 | 18.94 | 93% |
| 418 | internal tandem duplication | 1,497 | 1,591 | 18.94 | 94% |
| 419 | epidermal growth factor receptor mutation | 1,325 | 1,391 | 18.94 | 95% |
| 420 | influenza a(h1n1) | 1,665 | 1,784 | 18.94 | 93% |
| 421 | cancer theranostic | 2,018 | 2,180 | 18.94 | 93% |
| 422 | recurrent prostate cancer | 1,461 | 1,550 | 18.94 | 94% |
| 423 | classical hodgkin lymphoma | 1,380 | 1,456 | 18.94 | 95% |
| 424 | autoimmune hepatitis (aih) | 2,275 | 2,462 | 18.94 | 92% |
| 425 | human epidermal growth factor receptor-2 | 1,527 | 1,627 | 18.94 | 94% |
| 426 | advanced chronic kidney disease | 1,462 | 1,552 | 18.94 | 94% |
| 427 | time to progression (ttp) | 1,655 | 1,774 | 18.94 | 93% |
| 428 | cancer cell viability | 1,441 | 1,528 | 18.94 | 94% |
| 429 | alcohol use disorders identification test (audit) | 1,164 | 1,203 | 18.94 | 97% |
| 430 | highly pathogenic avian influenza virus | 1,332 | 1,401 | 18.94 | 95% |
| 431 | five-year overall survival | 1,958 | 2,116 | 18.94 | 93% |
| 432 | objective response rate (orr) | 3,631 | 3,847 | 18.94 | 94% |
| 433 | breast cancer subtypes | 2,695 | 2,909 | 18.94 | 93% |
| 434 | epithelial ovarian cancer (eoc) | 3,539 | 3,758 | 18.94 | 94% |
| 435 | opioid use disorder (oud) | 2,090 | 2,262 | 18.94 | 92% |
| 436 | trastuzumab | 2,293 | 2,483 | 18.94 | 92% |
| 437 | abirateron | 2,690 | 2,904 | 18.94 | 93% |
| 438 | abiraterone | 2,685 | 2,899 | 18.94 | 93% |
| 439 | non-muscle invasive | 1,795 | 1,934 | 18.94 | 93% |
| 440 | total lesion glycolysis | 1,375 | 1,452 | 18.94 | 95% |
| 441 | 5-year dfs | 1,590 | 1,701 | 18.94 | 93% |
| 442 | neoadjuvant chemotherapy (nact) | 1,369 | 1,445 | 18.94 | 95% |
| 443 | lifetime cancer risk | 2,024 | 2,190 | 18.94 | 92% |
| 444 | adults with diabetes | 2,864 | 3,085 | 18.94 | 93% |
| 445 | treatment-experienced | 1,729 | 1,860 | 18.94 | 93% |
| 446 | glucagon-like peptide-1 receptor agonists | 1,439 | 1,527 | 18.94 | 94% |
| 447 | alcohol use disorder (aud) | 2,837 | 3,058 | 18.94 | 93% |
| 448 | mucosa-associated lymphoid tissue (malt) lymphoma | 1,426 | 1,512 | 18.94 | 94% |
| 449 | diffuse large b cell | 3,485 | 3,708 | 18.94 | 94% |
| 450 | cancer mouse model | 1,450 | 1,540 | 18.94 | 94% |
| 451 | hcc progression | 2,375 | 2,573 | 18.94 | 92% |
| 452 | stroke centers | 1,228 | 1,280 | 18.94 | 96% |
| 453 | hiv viral load | 3,440 | 3,665 | 18.94 | 94% |
| 454 | obesity weight loss | 1,602 | 1,716 | 18.94 | 93% |
| 455 | receptor tyrosine kinase inhibitors | 1,552 | 1,659 | 18.94 | 94% |
| 456 | acute ischemic stroke (ais) | 3,805 | 4,019 | 18.94 | 95% |
| 457 | braf mutations | 2,632 | 2,847 | 18.94 | 92% |
| 458 | chronic thromboembolic | 2,802 | 3,024 | 18.94 | 93% |
| 459 | human hepatocellular carcinoma (hcc) | 1,940 | 2,099 | 18.94 | 92% |
| 460 | human prostate cancer cell line | 1,839 | 1,986 | 18.94 | 93% |
| 461 | programmed cell death ligand | 1,939 | 2,098 | 18.94 | 92% |
| 462 | advanced non-small-cell lung cancer | 3,154 | 3,383 | 18.94 | 93% |
| 463 | bxpc-3 | 1,643 | 1,764 | 18.94 | 93% |
| 464 | neoadjuvant setting | 1,690 | 1,818 | 18.94 | 93% |
| 465 | melanoma differentiation | 1,321 | 1,391 | 18.94 | 95% |
| 466 | pi-rads | 1,390 | 1,472 | 18.94 | 94% |
| 467 | enzalutamid | 2,566 | 2,780 | 18.94 | 92% |
| 468 | microsatellite stable | 1,323 | 1,394 | 18.94 | 95% |
| 469 | enzalutamide | 2,562 | 2,776 | 18.94 | 92% |
| 470 | anti-cancer activities | 1,770 | 1,910 | 18.94 | 93% |
| 471 | colorectal cancer cell lines | 2,010 | 2,179 | 18.94 | 92% |
| 472 | spoligotyping | 1,483 | 1,581 | 18.94 | 94% |
| 473 | type 1 diabetes mellitus (t1dm) | 4,036 | 4,242 | 18.94 | 95% |
| 474 | tyrosine kinase inhibitor (tki) | 3,011 | 3,242 | 18.94 | 93% |
| 475 | upper tract urothelial | 1,636 | 1,758 | 18.94 | 93% |
| 476 | tongue squamous cell carcinoma | 1,691 | 1,821 | 18.94 | 93% |
| 477 | protumor | 1,849 | 2,000 | 18.94 | 92% |
| 478 | chronic hiv | 1,705 | 1,837 | 18.94 | 93% |
| 479 | human hepatocellular carcinoma cells | 1,460 | 1,555 | 18.94 | 94% |
| 480 | targeted anticancer | 1,490 | 1,590 | 18.94 | 94% |
| 481 | advanced non-small cell lung cancer (nsclc) | 3,630 | 3,857 | 18.94 | 94% |
| 482 | chronic hepatitis c virus infection | 1,919 | 2,079 | 18.94 | 92% |
| 483 | common toxicity criteria | 1,507 | 1,610 | 18.94 | 94% |
| 484 | diabetes prevention program | 1,350 | 1,427 | 18.94 | 95% |
| 485 | human hepatocellular carcinoma cell | 2,520 | 2,734 | 18.94 | 92% |
| 486 | stable coronary artery disease (cad) | 1,151 | 1,192 | 18.94 | 97% |
| 487 | obesity paradox | 1,332 | 1,406 | 18.94 | 95% |
| 488 | stroke units | 1,518 | 1,623 | 18.94 | 94% |
| 489 | h7n9 | 1,939 | 2,102 | 18.94 | 92% |
| 490 | prostate cancer (cap) | 1,177 | 1,223 | 18.94 | 96% |
| 491 | prior stroke | 1,575 | 1,689 | 18.94 | 93% |
| 492 | pegylated interferon and ribavirin | 1,198 | 1,248 | 18.94 | 96% |
| 493 | stroke severity | 4,244 | 4,440 | 18.94 | 96% |
| 494 | cancer susceptibility gene | 2,261 | 2,457 | 18.94 | 92% |
| 495 | pediatric asthma | 2,457 | 2,668 | 18.94 | 92% |
| 496 | a(h1n1) | 2,708 | 2,933 | 18.94 | 92% |
| 497 | oral cancer cell | 1,672 | 1,801 | 18.94 | 93% |
| 498 | human neuroblastoma sh-sy5y cells | 1,250 | 1,310 | 18.94 | 95% |
| 499 | lymphovascular space | 1,239 | 1,297 | 18.94 | 96% |
| 500 | integrase inhibitors | 1,532 | 1,640 | 18.94 | 93% |
| 501 | cancer cell migration and invasion | 1,427 | 1,518 | 18.94 | 94% |
| 502 | insulin resistance obesity | 2,747 | 2,974 | 18.94 | 92% |
| 503 | clinical benefit rate | 1,322 | 1,395 | 18.94 | 95% |
| 504 | large b cell lymphoma | 3,569 | 3,801 | 18.94 | 94% |
| 505 | hepatitis c patients | 3,285 | 3,522 | 18.93 | 93% |
| 506 | sy5y neuroblastoma | 2,004 | 2,176 | 18.93 | 92% |
| 507 | hcv patients | 3,353 | 3,590 | 18.93 | 93% |
| 508 | uncomplicated malaria | 1,924 | 2,087 | 18.93 | 92% |
| 509 | antiretroviral regimen | 2,221 | 2,415 | 18.93 | 92% |
| 510 | hormone-refractory prostate cancer | 1,274 | 1,339 | 18.93 | 95% |
| 511 | cancer-associated fibroblasts (cafs) | 2,114 | 2,298 | 18.93 | 92% |
| 512 | xenograft tumor model | 2,240 | 2,436 | 18.93 | 92% |
| 513 | hepatitis c (hcv) | 2,174 | 2,364 | 18.93 | 92% |
| 514 | and type 1 diabetes | 2,017 | 2,191 | 18.93 | 92% |
| 515 | stage i nsclc | 1,170 | 1,216 | 18.93 | 96% |
| 516 | cervical cancer (cc) | 2,016 | 2,190 | 18.93 | 92% |
| 517 | hiv cohort | 1,245 | 1,305 | 18.93 | 95% |
| 518 | a/h1n1 | 1,920 | 2,083 | 18.93 | 92% |
| 519 | nodal staging | 1,463 | 1,561 | 18.93 | 94% |
| 520 | nk/t-cell lymphoma | 1,283 | 1,350 | 18.93 | 95% |
| 521 | chronic thromboemboli | 2,852 | 3,085 | 18.93 | 92% |
| 522 | secondary stroke | 1,510 | 1,616 | 18.93 | 93% |
| 523 | treatment of chronic hepatitis c | 2,065 | 2,245 | 18.93 | 92% |
| 524 | cancer apoptosis | 1,434 | 1,528 | 18.93 | 94% |
| 525 | european organization for research and treatment of cancer | 3,843 | 4,069 | 18.93 | 94% |
| 526 | thromboembolic pulmonary hypertension | 2,575 | 2,797 | 18.93 | 92% |
| 527 | anti-obesity effects | 1,329 | 1,405 | 18.93 | 95% |
| 528 | multikinase inhibitor | 1,754 | 1,897 | 18.93 | 92% |
| 529 | response evaluation criteria in solid tumors | 3,783 | 4,012 | 18.93 | 94% |
| 530 | folfox | 3,932 | 4,154 | 18.93 | 95% |
| 531 | cancer drug delivery | 3,371 | 3,611 | 18.93 | 93% |
| 532 | asthma quality of life | 1,197 | 1,249 | 18.93 | 96% |
| 533 | diabetes diagnosis | 2,381 | 2,591 | 18.93 | 92% |
| 534 | chronic kidney disease patients | 2,906 | 3,143 | 18.93 | 92% |
| 535 | nk/t-cell | 1,343 | 1,422 | 18.93 | 94% |
| 536 | cancer specific survival | 1,478 | 1,580 | 18.93 | 94% |
| 537 | cancer cell death | 3,763 | 3,994 | 18.93 | 94% |
| 538 | colorectal cancer cell line | 3,022 | 3,262 | 18.93 | 93% |
| 539 | hnscc cell lines | 1,205 | 1,259 | 18.93 | 96% |
| 540 | current asthma | 1,932 | 2,099 | 18.93 | 92% |
| 541 | hmlh | 1,782 | 1,930 | 18.93 | 92% |
| 542 | mcf-7 cancer cell | 1,290 | 1,360 | 18.93 | 95% |
| 543 | art initiation | 3,883 | 4,110 | 18.93 | 94% |
| 544 | hcv replication | 2,191 | 2,386 | 18.93 | 92% |
| 545 | esophageal cancer cell | 1,795 | 1,945 | 18.93 | 92% |
| 546 | influenza-like illness (ili) | 1,300 | 1,372 | 18.93 | 95% |
| 547 | mtb/rif | 1,943 | 2,112 | 18.93 | 92% |
| 548 | her2-overexpressing | 1,196 | 1,249 | 18.93 | 96% |
| 549 | androgen-independent prostate cancer | 1,243 | 1,305 | 18.93 | 95% |
| 550 | direct-acting antivirals (daas) | 1,216 | 1,273 | 18.93 | 96% |
| 551 | chronic kidney disease stage | 1,297 | 1,369 | 18.93 | 95% |
| 552 | drug use disorder | 1,439 | 1,536 | 18.93 | 94% |
| 553 | in vitro anticancer activity | 1,599 | 1,722 | 18.93 | 93% |
| 554 | muscle-invasive bladder cancer | 3,993 | 4,217 | 18.93 | 95% |
| 555 | hepatitis e virus (hev) | 3,489 | 3,732 | 18.93 | 93% |
| 556 | recurrence-free survival rate | 1,950 | 2,121 | 18.93 | 92% |
| 557 | colorectal carcinoma (crc) | 1,712 | 1,852 | 18.93 | 92% |
| 558 | severe stroke | 1,813 | 1,967 | 18.93 | 92% |
| 559 | tb diagnosis | 2,100 | 2,288 | 18.93 | 92% |
| 560 | colorectal cancer liver metastases | 1,223 | 1,282 | 18.93 | 95% |
| 561 | hcv coinfection | 1,165 | 1,213 | 18.93 | 96% |
| 562 | human lung cancer cells | 2,485 | 2,706 | 18.93 | 92% |
| 563 | drug-resistant cancer | 1,304 | 1,378 | 18.93 | 95% |
| 564 | diffuse large b cell lymphoma (dlbcl) | 1,354 | 1,437 | 18.93 | 94% |
| 565 | braf inhibitor | 2,360 | 2,572 | 18.93 | 92% |
| 566 | adults with cancer | 1,751 | 1,897 | 18.93 | 92% |
| 567 | direct-acting antiviral agent | 1,330 | 1,409 | 18.93 | 94% |
| 568 | endovascular thrombectomy | 1,505 | 1,614 | 18.93 | 93% |
| 569 | cancer gene expression | 2,257 | 2,461 | 18.93 | 92% |
| 570 | clinicopathologic factors | 2,740 | 2,976 | 18.93 | 92% |
| 571 | hepatitis c virus (hcv) genotype | 1,231 | 1,292 | 18.93 | 95% |
| 572 | atezolizumab | 2,267 | 2,472 | 18.93 | 92% |
| 573 | highly pathogenic avian influenza | 3,550 | 3,794 | 18.93 | 94% |
| 574 | brca1 and brca2 mutation | 1,268 | 1,336 | 18.93 | 95% |
| 575 | breast cancer stem cell | 1,865 | 2,027 | 18.93 | 92% |
| 576 | liver cancer cells | 3,197 | 3,445 | 18.93 | 93% |
| 577 | tumor cell apoptosis | 2,550 | 2,777 | 18.93 | 92% |
| 578 | cancer targeted therapy | 1,287 | 1,359 | 18.93 | 95% |
| 579 | pancreatic cancer (pc) | 2,742 | 2,980 | 18.93 | 92% |
| 580 | recovery after stroke | 1,670 | 1,806 | 18.93 | 92% |
| 581 | response evaluation criteria in solid tumor | 3,917 | 4,150 | 18.93 | 94% |
| 582 | cvd mortality | 2,718 | 2,955 | 18.93 | 92% |
| 583 | child obesity | 1,558 | 1,677 | 18.93 | 93% |
| 584 | chronic hepatitis c infection | 1,514 | 1,626 | 18.93 | 93% |
| 585 | organ-confined | 2,159 | 2,356 | 18.93 | 92% |
| 586 | prostate cancer screening | 2,557 | 2,786 | 18.93 | 92% |
| 587 | adult congenital heart disease | 1,800 | 1,955 | 18.93 | 92% |
| 588 | artemisinin-based combination | 1,742 | 1,889 | 18.93 | 92% |
| 589 | nonsmall cell lung | 3,412 | 3,662 | 18.93 | 93% |
| 590 | 22rv1 | 1,197 | 1,253 | 18.93 | 96% |
| 591 | cancer registry data | 2,392 | 2,610 | 18.93 | 92% |
| 592 | ribavirin (rbv) | 1,457 | 1,560 | 18.93 | 93% |
| 593 | overall and disease-free survival | 2,575 | 2,806 | 18.93 | 92% |
| 594 | prostate cancer risk | 3,860 | 4,098 | 18.93 | 94% |
| 595 | in vitro anticancer | 2,844 | 3,088 | 18.93 | 92% |
| 596 | adult cancer survivors | 1,053 | 1,081 | 18.93 | 97% |
| 597 | clinically localized prostate cancer | 2,101 | 2,293 | 18.93 | 92% |
| 598 | influenza a (h1n1) | 2,569 | 2,800 | 18.93 | 92% |
| 599 | circumferential resection margin | 1,221 | 1,282 | 18.93 | 95% |
| 600 | melanoma progression | 2,035 | 2,220 | 18.93 | 92% |
| 601 | subtypes of breast cancer | 1,743 | 1,891 | 18.93 | 92% |
| 602 | pulmonary tuberculosis (ptb) | 1,687 | 1,827 | 18.93 | 92% |
| 603 | uterine cervical neoplasm | 1,714 | 1,858 | 18.93 | 92% |
| 604 | nnrtis | 2,086 | 2,277 | 18.93 | 92% |
| 605 | advanced hepatocellular carcinoma | 3,404 | 3,656 | 18.93 | 93% |
| 606 | hereditary breast and ovarian cancer | 1,417 | 1,514 | 18.93 | 94% |
| 607 | mda-mb-468 | 2,030 | 2,215 | 18.93 | 92% |
| 608 | thyroid cancer cell | 1,995 | 2,176 | 18.93 | 92% |
| 609 | diffuse large b-cell lymphomas | 1,283 | 1,356 | 18.93 | 95% |
| 610 | asthma children | 2,836 | 3,081 | 18.93 | 92% |
| 611 | children with obesity | 1,365 | 1,453 | 18.93 | 94% |
| 612 | human gastric cancer cells | 1,636 | 1,769 | 18.93 | 92% |
| 613 | pcr rate | 1,497 | 1,608 | 18.93 | 93% |
| 614 | egfr-mutated | 1,308 | 1,386 | 18.93 | 94% |
| 615 | circulating tumor dna (ctdna) | 2,007 | 2,190 | 18.93 | 92% |
| 616 | platinum-resistant | 1,544 | 1,663 | 18.93 | 93% |
| 617 | hev infection | 2,057 | 2,246 | 18.93 | 92% |
| 618 | cancer quality of life | 4,373 | 4,583 | 18.92 | 95% |
| 619 | human pancreatic cancer cells | 1,481 | 1,590 | 18.92 | 93% |
| 620 | chronic kidney disease patient | 3,057 | 3,310 | 18.92 | 92% |
| 621 | stroke event | 2,008 | 2,192 | 18.92 | 92% |
| 622 | peginterferon | 2,722 | 2,964 | 18.92 | 92% |
| 623 | urinary bladder neoplasm | 1,854 | 2,019 | 18.92 | 92% |
| 624 | active surveillance (as) | 1,137 | 1,183 | 18.92 | 96% |
| 625 | breast cancer surgery | 3,003 | 3,255 | 18.92 | 92% |
| 626 | combination antiretroviral therapy | 3,867 | 4,109 | 18.92 | 94% |
| 627 | hbeag-negative | 1,597 | 1,725 | 18.92 | 93% |
| 628 | clinicopathologic factor | 2,783 | 3,028 | 18.92 | 92% |
| 629 | du145 cells | 1,708 | 1,853 | 18.92 | 92% |
| 630 | pc3 cells | 2,553 | 2,786 | 18.92 | 92% |
| 631 | reproductive healthcare | 2,005 | 2,189 | 18.92 | 92% |
| 632 | obesity and metabolic syndrome | 2,075 | 2,267 | 18.92 | 92% |
| 633 | middle east respiratory syndrome coronavirus | 1,937 | 2,113 | 18.92 | 92% |
| 634 | du145 cell | 1,889 | 2,059 | 18.92 | 92% |
| 635 | vitro anticancer activity | 1,741 | 1,891 | 18.92 | 92% |
| 636 | xenograft mice | 1,588 | 1,715 | 18.92 | 93% |
| 637 | axillary lymph node dissection (alnd) | 1,346 | 1,432 | 18.92 | 94% |
| 638 | clinically significant prostate cancer | 1,264 | 1,335 | 18.92 | 95% |
| 639 | type 2 diabetes (t2dm) | 4,072 | 4,305 | 18.92 | 95% |
| 640 | obesity and insulin resistance | 3,638 | 3,890 | 18.92 | 94% |
| 641 | acute stroke treatment | 1,195 | 1,253 | 18.92 | 95% |
| 642 | sh-sy5y neuroblastoma cells | 1,504 | 1,618 | 18.92 | 93% |
| 643 | panitumumab | 1,866 | 2,034 | 18.92 | 92% |
| 644 | lung cancer (lc) | 1,533 | 1,652 | 18.92 | 93% |
| 645 | metastasis prognosis | 1,934 | 2,111 | 18.92 | 92% |
| 646 | asthma exacerbations | 4,136 | 4,367 | 18.92 | 95% |
| 647 | ascvd | 2,614 | 2,853 | 18.92 | 92% |
| 648 | anti-cancer effects | 3,731 | 3,982 | 18.92 | 94% |
| 649 | high-grade serous | 3,145 | 3,403 | 18.92 | 92% |
| 650 | tobacco dependence | 2,138 | 2,339 | 18.92 | 91% |
| 651 | cancer survivorship | 3,409 | 3,668 | 18.92 | 93% |
| 652 | progression-free survival rate | 2,116 | 2,315 | 18.92 | 91% |
| 653 | baseline cd4 | 2,079 | 2,274 | 18.92 | 91% |
| 654 | latent tb | 2,345 | 2,566 | 18.92 | 91% |
| 655 | international prognostic index (ipi) | 1,143 | 1,192 | 18.92 | 96% |
| 656 | anticancer therapeutics | 1,562 | 1,687 | 18.92 | 93% |
| 657 | post-stroke patient | 1,773 | 1,930 | 18.92 | 92% |
| 658 | clinicopathologic parameter | 2,365 | 2,588 | 18.92 | 91% |
| 659 | orthotopic xenograft | 1,805 | 1,967 | 18.92 | 92% |
| 660 | sorafenib treatment | 1,171 | 1,226 | 18.92 | 96% |
| 661 | programmed cell death protein 1 | 2,458 | 2,689 | 18.92 | 91% |
| 662 | hcc cell lines | 3,993 | 4,236 | 18.92 | 94% |
| 663 | urinary bladder neoplasms | 1,726 | 1,877 | 18.92 | 92% |
| 664 | stroke, myocardial infarction | 2,131 | 2,333 | 18.92 | 91% |
| 665 | tyrosine kinase inhibitors (tki) | 1,360 | 1,451 | 18.92 | 94% |
| 666 | cancer cell cycle | 2,111 | 2,311 | 18.92 | 91% |
| 667 | hereditary breast | 3,335 | 3,597 | 18.92 | 93% |
| 668 | progression-free and overall survival | 2,397 | 2,624 | 18.92 | 91% |
| 669 | lymphovascular invasion (lvi) | 1,099 | 1,140 | 18.92 | 96% |
| 670 | imaging prostate cancer | 1,164 | 1,218 | 18.92 | 96% |
| 671 | substance use problem | 1,555 | 1,680 | 18.92 | 93% |
| 672 | lenvatinib | 1,702 | 1,850 | 18.92 | 92% |
| 673 | clinicopathologic parameters | 2,344 | 2,567 | 18.92 | 91% |
| 674 | urothelial carcinoma of the bladder | 1,245 | 1,315 | 18.92 | 95% |
| 675 | stroke risk factors | 2,077 | 2,274 | 18.92 | 91% |
| 676 | cancer theranostics | 1,667 | 1,810 | 18.92 | 92% |
| 677 | acute myeloid leukemia patient | 1,435 | 1,540 | 18.92 | 93% |
| 678 | androgen-deprivation | 1,306 | 1,388 | 18.92 | 94% |
| 679 | post-stroke patients | 1,717 | 1,868 | 18.92 | 92% |
| 680 | obesity risk | 3,762 | 4,018 | 18.92 | 94% |
| 681 | liver cancer cell line | 1,427 | 1,531 | 18.92 | 93% |
| 682 | mother-to-child transmission of hiv | 1,593 | 1,725 | 18.92 | 92% |
| 683 | first-line setting | 1,237 | 1,306 | 18.92 | 95% |
| 684 | metastatic non-small cell lung cancer | 1,489 | 1,604 | 18.92 | 93% |
| 685 | invasive coronary angiography | 2,261 | 2,478 | 18.92 | 91% |
| 686 | hiv antiretroviral therapy | 1,070 | 1,106 | 18.92 | 97% |
| 687 | lymph node metastasis (lnm) | 1,741 | 1,896 | 18.92 | 92% |
| 688 | insulin glargine | 2,360 | 2,586 | 18.92 | 91% |
| 689 | anti-hev | 1,476 | 1,589 | 18.92 | 93% |
| 690 | cancer disparities | 1,341 | 1,430 | 18.92 | 94% |
| 691 | ear cancer | 1,706 | 1,856 | 18.92 | 92% |
| 692 | neoadjuvant chemotherapy | 3,487 | 3,751 | 18.92 | 93% |
| 693 | clear cell renal cell carcinoma (ccrcc) | 2,994 | 3,255 | 18.92 | 92% |
| 694 | detectable viral load | 1,930 | 2,111 | 18.92 | 91% |
| 695 | r-chop | 2,618 | 2,863 | 18.92 | 91% |
| 696 | asthma care | 1,945 | 2,128 | 18.92 | 91% |
| 697 | insulin glargin | 2,378 | 2,606 | 18.92 | 91% |
| 698 | lung cancer prognosis | 2,044 | 2,239 | 18.92 | 91% |
| 699 | anti-cancer therapy | 2,856 | 3,113 | 18.92 | 92% |
| 700 | immunosuppressive tumor microenvironment | 1,503 | 1,621 | 18.92 | 93% |
| 701 | pre-exposure prophylaxis (prep) | 3,104 | 3,368 | 18.92 | 92% |
| 702 | stroke risk factor | 2,424 | 2,656 | 18.92 | 91% |
| 703 | brca1 brca2 | 1,865 | 2,038 | 18.92 | 92% |
| 704 | cancer gene therapy | 3,308 | 3,574 | 18.92 | 93% |
| 705 | uterine cervical neoplasms | 1,550 | 1,676 | 18.92 | 92% |
| 706 | cervical cancer cell line | 2,421 | 2,653 | 18.92 | 91% |
| 707 | basal-like | 3,229 | 3,495 | 18.92 | 92% |
| 708 | asthma guideline | 1,171 | 1,228 | 18.92 | 95% |
| 709 | h1n1 pandemic | 1,442 | 1,550 | 18.92 | 93% |
| 710 | head and neck squamous cell carcinomas | 2,192 | 2,404 | 18.92 | 91% |
| 711 | definitive chemoradiotherapy | 1,135 | 1,185 | 18.92 | 96% |
| 712 | substance use problems | 1,453 | 1,563 | 18.92 | 93% |
| 713 | hiv-1 entry | 1,195 | 1,257 | 18.92 | 95% |
| 714 | hbv genotypes | 1,179 | 1,238 | 18.92 | 95% |
| 715 | xenograft growth | 1,533 | 1,657 | 18.92 | 93% |
| 716 | programmed death-ligand 1 | 3,109 | 3,375 | 18.92 | 92% |
| 717 | hiv clinics | 1,229 | 1,298 | 18.92 | 95% |
| 718 | ovarian cancer (oc) | 2,649 | 2,898 | 18.92 | 91% |
| 719 | sentinel lymph nodes | 3,510 | 3,777 | 18.92 | 93% |
| 720 | inflammation and cancer | 2,329 | 2,555 | 18.92 | 91% |
| 721 | hiv risk behavior | 1,969 | 2,157 | 18.92 | 91% |
| 722 | advanced/metastatic | 1,142 | 1,194 | 18.92 | 96% |
| 723 | programmed death ligand 1 | 2,035 | 2,231 | 18.92 | 91% |
| 724 | hereditary breast cancer | 1,506 | 1,626 | 18.92 | 93% |
| 725 | egfr-mutant | 1,541 | 1,667 | 18.92 | 92% |
| 726 | ovarian cancer risk | 1,798 | 1,964 | 18.92 | 92% |
| 727 | metastatic pancreatic cancer | 1,563 | 1,693 | 18.92 | 92% |
| 728 | brca mutations | 1,314 | 1,400 | 18.92 | 94% |
| 729 | high hiv prevalence | 1,423 | 1,529 | 18.92 | 93% |
| 730 | antenatal care (anc) | 2,020 | 2,215 | 18.92 | 91% |
| 731 | k103n | 994 | 1,016 | 18.92 | 98% |
| 732 | hiv drug resistance | 1,456 | 1,568 | 18.92 | 93% |
| 733 | substance use disorder treatment | 1,144 | 1,197 | 18.92 | 96% |
| 734 | long-acting reversible | 1,610 | 1,748 | 18.92 | 92% |
| 735 | obesity and overweight | 2,198 | 2,413 | 18.92 | 91% |
| 736 | hiv services | 1,609 | 1,747 | 18.92 | 92% |
| 737 | cervical cancer prevention | 1,766 | 1,928 | 18.92 | 92% |
| 738 | breslow thickness | 1,491 | 1,610 | 18.92 | 93% |
| 739 | raltegravir | 1,875 | 2,053 | 18.92 | 91% |
| 740 | ras wild-type | 1,200 | 1,265 | 18.92 | 95% |
| 741 | plasma viral load | 2,297 | 2,523 | 18.92 | 91% |
| 742 | osimertinib | 1,989 | 2,182 | 18.92 | 91% |
| 743 | pre-diabetes | 2,421 | 2,658 | 18.92 | 91% |
| 744 | non-small cell lung cancer patients | 3,484 | 3,756 | 18.91 | 93% |
| 745 | colorectal cancer surgery | 1,665 | 1,813 | 18.91 | 92% |
| 746 | recurrence survival | 1,723 | 1,880 | 18.91 | 92% |
| 747 | significant cancer | 1,376 | 1,475 | 18.91 | 93% |
| 748 | epithelial–mesenchymal transition (emt) | 2,312 | 2,540 | 18.91 | 91% |
| 749 | melanoma treatment | 1,569 | 1,702 | 18.91 | 92% |
| 750 | aml cell lines | 1,326 | 1,416 | 18.91 | 94% |
| 751 | hiv-1 vaccine | 1,611 | 1,751 | 18.91 | 92% |
| 752 | viral load (vl) | 1,881 | 2,061 | 18.91 | 91% |
| 753 | chemoradiation therapy | 3,380 | 3,654 | 18.91 | 93% |
| 754 | hiv diagnosis | 3,926 | 4,187 | 18.91 | 94% |
| 755 | paclitaxel and carboplatin | 1,211 | 1,279 | 18.91 | 95% |
| 756 | hev rna | 1,107 | 1,154 | 18.91 | 96% |
| 757 | rectal cancer treatment | 1,433 | 1,543 | 18.91 | 93% |
| 758 | influenza a virus (iav) | 2,208 | 2,427 | 18.91 | 91% |
| 759 | human liver cancer | 2,010 | 2,207 | 18.91 | 91% |
| 760 | rectal cancer resection | 1,116 | 1,165 | 18.91 | 96% |
| 761 | sporadic colorectal cancer | 1,414 | 1,521 | 18.91 | 93% |
| 762 | prostate cancer cell lines | 4,375 | 4,611 | 18.91 | 95% |
| 763 | serous ovarian cancer | 2,455 | 2,697 | 18.91 | 91% |
| 764 | pcnsl | 1,980 | 2,174 | 18.91 | 91% |
| 765 | breast cancer xenograft | 1,369 | 1,468 | 18.91 | 93% |
| 766 | human pancreatic cancer cell | 2,547 | 2,796 | 18.91 | 91% |
| 767 | methicillin-resistant s. aureus (mrsa) | 2,827 | 3,092 | 18.91 | 91% |
| 768 | hiv-1-infected patients | 2,742 | 3,003 | 18.91 | 91% |
| 769 | cancer stem cell marker | 1,373 | 1,473 | 18.91 | 93% |
| 770 | advanced rectal cancer | 4,126 | 4,380 | 18.91 | 94% |
| 771 | lymph node staging | 1,512 | 1,637 | 18.91 | 92% |
| 772 | stroke outcome | 4,016 | 4,276 | 18.91 | 94% |
| 773 | obesity intervention | 1,176 | 1,238 | 18.91 | 95% |
| 774 | retention in care | 1,535 | 1,664 | 18.91 | 92% |
| 775 | post stroke | 2,370 | 2,606 | 18.91 | 91% |
| 776 | overweight or obesity | 4,023 | 4,283 | 18.91 | 94% |
| 777 | triple negative breast cancer (tnbc) | 2,229 | 2,452 | 18.91 | 91% |
| 778 | complicated malaria | 2,188 | 2,407 | 18.91 | 91% |
| 779 | gleason grade | 2,422 | 2,663 | 18.91 | 91% |
| 780 | breast cancer recurrence | 2,025 | 2,226 | 18.91 | 91% |
| 781 | novel anticancer agent | 1,379 | 1,481 | 18.91 | 93% |
| 782 | nucleos(t)ide analogue | 1,253 | 1,331 | 18.91 | 94% |
| 783 | non-small cell lung cancer cell | 3,014 | 3,288 | 18.91 | 92% |
| 784 | avian influenza viruses | 2,943 | 3,215 | 18.91 | 92% |
| 785 | chemical failure | 2,179 | 2,398 | 18.91 | 91% |
| 786 | cannabis use disorder | 1,405 | 1,512 | 18.91 | 93% |
| 787 | papillary thyroid carcinoma (ptc) | 4,267 | 4,515 | 18.91 | 95% |
| 788 | asthma prevalence | 1,774 | 1,942 | 18.91 | 91% |
| 789 | radical cystectomy (rc) | 1,516 | 1,643 | 18.91 | 92% |
| 790 | anaplastic thyroid cancer | 1,318 | 1,409 | 18.91 | 94% |
| 791 | breast cancer therapy | 3,140 | 3,418 | 18.91 | 92% |
| 792 | ecog ps | 1,265 | 1,346 | 18.91 | 94% |
| 793 | triple-negative breast cancers | 1,159 | 1,219 | 18.91 | 95% |
| 794 | breast cancer stem cells | 1,553 | 1,687 | 18.91 | 92% |
| 795 | her2+ | 3,392 | 3,673 | 18.91 | 92% |
| 796 | kidney disease progression | 1,284 | 1,369 | 18.91 | 94% |
| 797 | direct acting antiviral | 1,460 | 1,578 | 18.91 | 93% |
| 798 | hiv knowledge | 1,426 | 1,538 | 18.91 | 93% |
| 799 | cancer stemness | 1,504 | 1,630 | 18.91 | 92% |
| 800 | platinum-sensitive | 1,221 | 1,294 | 18.91 | 94% |
| 801 | cause-specific survival | 2,141 | 2,358 | 18.91 | 91% |
| 802 | xenograft tumors | 3,825 | 4,099 | 18.91 | 93% |
| 803 | exon 19 deletion | 1,181 | 1,246 | 18.91 | 95% |
| 804 | transcatheter arterial chemoembolization | 2,914 | 3,188 | 18.91 | 91% |
| 805 | osteosarcoma (os) | 2,965 | 3,241 | 18.91 | 91% |
| 806 | human gastric cancer cell | 2,961 | 3,237 | 18.91 | 91% |
| 807 | dengue virus (denv) | 3,760 | 4,037 | 18.91 | 93% |
| 808 | kidney disease: improving global outcomes | 1,199 | 1,268 | 18.91 | 95% |
| 809 | checkpoint inhibition | 2,370 | 2,611 | 18.91 | 91% |
| 810 | stroke recovery | 2,325 | 2,562 | 18.91 | 91% |
| 811 | tumor xenograft model | 1,933 | 2,126 | 18.91 | 91% |
| 812 | mda-mb-435 | 1,585 | 1,726 | 18.91 | 92% |
| 813 | bcr-abl1 | 2,018 | 2,222 | 18.91 | 91% |
| 814 | hepatocellular carcinoma cell line | 2,280 | 2,513 | 18.91 | 91% |
| 815 | papillary renal cell carcinoma | 1,441 | 1,557 | 18.91 | 93% |
| 816 | coronary artery calcium (cac) | 1,463 | 1,583 | 18.91 | 92% |
| 817 | asthma risk | 1,261 | 1,343 | 18.91 | 94% |
| 818 | tumor-associated macrophages (tams) | 2,508 | 2,761 | 18.91 | 91% |
| 819 | hiv-positive men | 1,364 | 1,466 | 18.91 | 93% |
| 820 | entecavir | 2,958 | 3,236 | 18.91 | 91% |
| 821 | du-145 | 2,095 | 2,309 | 18.91 | 91% |
| 822 | cancer strategy | 1,233 | 1,310 | 18.91 | 94% |
| 823 | disease-free and overall survival | 2,602 | 2,863 | 18.91 | 91% |
| 824 | drug-resistant tb | 2,285 | 2,520 | 18.91 | 91% |
| 825 | ajcc stage | 1,572 | 1,712 | 18.91 | 92% |
| 826 | aggressive prostate cancer | 1,227 | 1,303 | 18.91 | 94% |
| 827 | panc-1 cells | 1,644 | 1,796 | 18.91 | 92% |
| 828 | secondary stroke prevention | 1,267 | 1,351 | 18.91 | 94% |
| 829 | small cell lung cancer cells | 2,488 | 2,741 | 18.91 | 91% |
| 830 | ns5a | 2,710 | 2,978 | 18.91 | 91% |
| 831 | diabetes self-care | 1,365 | 1,468 | 18.91 | 93% |
| 832 | cancer outcomes | 4,317 | 4,571 | 18.91 | 94% |
| 833 | pathological complete response | 3,893 | 4,170 | 18.91 | 93% |
| 834 | human non-small cell lung cancer | 1,839 | 2,021 | 18.91 | 91% |
| 835 | clinicopathological variables | 2,637 | 2,901 | 18.91 | 91% |
| 836 | oncolytic adenovirus | 1,369 | 1,473 | 18.91 | 93% |
| 837 | global initiative for asthma | 1,071 | 1,115 | 18.91 | 96% |
| 838 | androgen-deprivation therapy | 1,186 | 1,254 | 18.91 | 95% |
| 839 | esophageal cancer patients | 2,619 | 2,882 | 18.91 | 91% |
| 840 | kras mutations | 3,499 | 3,786 | 18.91 | 92% |
| 841 | carcinoma hepatocellular | 3,251 | 3,538 | 18.91 | 92% |
| 842 | cardioembolic stroke | 2,024 | 2,231 | 18.91 | 91% |
| 843 | clinicopathological variable | 2,677 | 2,944 | 18.91 | 91% |
| 844 | panc-1 cell | 1,850 | 2,034 | 18.91 | 91% |
| 845 | syntax score | 1,621 | 1,770 | 18.91 | 92% |
| 846 | non-muscle invasive bladder cancer | 1,383 | 1,490 | 18.91 | 93% |
| 847 | recist criteria | 1,279 | 1,366 | 18.91 | 94% |
| 848 | stroke care | 3,790 | 4,072 | 18.91 | 93% |
| 849 | xpert mtb/rif | 1,620 | 1,769 | 18.91 | 92% |
| 850 | incident cancer | 1,572 | 1,713 | 18.91 | 92% |
| 851 | scchn | 1,675 | 1,833 | 18.91 | 91% |
| 852 | high-risk neuroblastoma | 1,258 | 1,341 | 18.91 | 94% |
| 853 | hepatitis g virus | 1,008 | 1,039 | 18.91 | 97% |
| 854 | hbv reactivation | 1,193 | 1,263 | 18.91 | 94% |
| 855 | primary hcc | 1,242 | 1,322 | 18.91 | 94% |
| 856 | diabetes prevention | 3,956 | 4,233 | 18.91 | 93% |
| 857 | human cervical cancer | 3,143 | 3,430 | 18.91 | 92% |
| 858 | pik3ca mutation | 1,922 | 2,117 | 18.91 | 91% |
| 859 | people with stroke | 1,177 | 1,244 | 18.91 | 95% |
| 860 | metastasis-free survival | 4,475 | 4,721 | 18.91 | 95% |
| 861 | xpert mtb | 1,670 | 1,828 | 18.91 | 91% |
| 862 | egfr tyrosine kinase | 3,736 | 4,022 | 18.91 | 93% |
| 863 | anthracycline-based chemotherapy | 1,113 | 1,167 | 18.91 | 95% |
| 864 | brafv600e | 2,404 | 2,653 | 18.91 | 91% |
| 865 | anti-tuberculosis treatment | 1,325 | 1,422 | 18.91 | 93% |
| 866 | highly pathogenic avian influenza (hpai) | 1,335 | 1,434 | 18.91 | 93% |
| 867 | anti-pd-l1 | 2,401 | 2,650 | 18.91 | 91% |
| 868 | raf inhibitors | 1,717 | 1,883 | 18.91 | 91% |
| 869 | cancer thyroid | 2,097 | 2,315 | 18.91 | 91% |
| 870 | children obesity | 1,318 | 1,414 | 18.9 | 93% |
| 871 | nonsmall cell | 3,515 | 3,806 | 18.9 | 92% |
| 872 | non-small cell lung carcinoma (nsclc) | 1,450 | 1,571 | 18.9 | 92% |
| 873 | type 2 diabetes risk | 1,247 | 1,329 | 18.9 | 94% |
| 874 | psma pet | 1,272 | 1,359 | 18.9 | 94% |
| 875 | asthma medication | 2,556 | 2,818 | 18.9 | 91% |
| 876 | pneumonia severity | 1,227 | 1,305 | 18.9 | 94% |
| 877 | dipeptidyl peptidase-4 inhibitor | 2,361 | 2,607 | 18.9 | 91% |
| 878 | esat-6 | 1,477 | 1,603 | 18.9 | 92% |
| 879 | direct-acting antiviral agents | 1,211 | 1,286 | 18.9 | 94% |
| 880 | national comprehensive cancer network (nccn) | 1,133 | 1,192 | 18.9 | 95% |
| 881 | egfr inhibitors | 2,708 | 2,981 | 18.9 | 91% |
| 882 | programmed death-ligand | 3,238 | 3,530 | 18.9 | 92% |
| 883 | breast cancer cell proliferation | 1,878 | 2,069 | 18.9 | 91% |
| 884 | anticancer treatments | 1,501 | 1,632 | 18.9 | 92% |
| 885 | type 1 dm | 1,397 | 1,509 | 18.9 | 93% |
| 886 | egfr-tki | 4,172 | 4,443 | 18.9 | 94% |
| 887 | vascular space invasion | 1,456 | 1,579 | 18.9 | 92% |
| 888 | metastasectomy | 2,635 | 2,904 | 18.9 | 91% |
| 889 | middle east respiratory syndrome coronavirus (mers-cov) | 1,407 | 1,521 | 18.9 | 93% |
| 890 | cancer intervention | 1,528 | 1,664 | 18.9 | 92% |
| 891 | cancer aggressiveness | 1,401 | 1,514 | 18.9 | 93% |
| 892 | type 2 diabetic rat | 1,669 | 1,829 | 18.9 | 91% |
| 893 | incident cardiovascular disease | 1,121 | 1,178 | 18.9 | 95% |
| 894 | csc marker | 1,236 | 1,317 | 18.9 | 94% |
| 895 | oral cancer cells | 1,231 | 1,311 | 18.9 | 94% |
| 896 | hcc diagnosis | 1,162 | 1,228 | 18.9 | 95% |
| 897 | late toxicities | 1,696 | 1,861 | 18.9 | 91% |
| 898 | crizotinib | 2,778 | 3,057 | 18.9 | 91% |
| 899 | breast and prostate cancer | 2,480 | 2,739 | 18.9 | 91% |
| 900 | cancer resistance | 4,144 | 4,419 | 18.9 | 94% |
| 901 | b-cell lymphoma 2 (bcl-2) | 1,478 | 1,606 | 18.9 | 92% |
| 902 | pulmonary tuberculosis (tb) | 1,701 | 1,867 | 18.9 | 91% |
| 903 | quantiferon | 2,175 | 2,405 | 18.9 | 90% |
| 904 | cardiovascular and cerebrovascular diseases | 1,528 | 1,665 | 18.9 | 92% |
| 905 | oncogenic function | 2,211 | 2,445 | 18.9 | 90% |
| 906 | disease-specific survival rate | 1,118 | 1,175 | 18.9 | 95% |
| 907 | lung cancer a549 cell | 1,174 | 1,243 | 18.9 | 94% |
| 908 | usual interstitial pneumonia | 1,755 | 1,930 | 18.9 | 91% |
| 909 | adherence to antiretroviral therapy | 1,368 | 1,476 | 18.9 | 93% |
| 910 | rassf1 | 1,869 | 2,061 | 18.9 | 91% |
| 911 | diabetes mellitus type 1 | 1,848 | 2,037 | 18.9 | 91% |
| 912 | antiretroviral medication | 1,588 | 1,736 | 18.9 | 91% |
| 913 | er-positive breast cancer | 1,357 | 1,463 | 18.9 | 93% |
| 914 | micropapillary | 1,903 | 2,100 | 18.9 | 91% |
| 915 | immune-related adverse events (iraes) | 1,628 | 1,783 | 18.9 | 91% |
| 916 | laryngeal squamous cell carcinoma | 2,495 | 2,757 | 18.9 | 90% |
| 917 | advanced melanoma | 3,106 | 3,400 | 18.9 | 91% |
| 918 | tumor necrosis factor-related | 2,947 | 3,236 | 18.9 | 91% |
| 919 | the cancer genome atlas database | 1,573 | 1,719 | 18.9 | 92% |
| 920 | latent tb infection | 1,550 | 1,692 | 18.9 | 92% |
| 921 | cancer information | 1,631 | 1,787 | 18.9 | 91% |
| 922 | hormone receptor (hr) | 1,100 | 1,154 | 18.9 | 95% |
| 923 | type 1 diabetes patients | 1,209 | 1,286 | 18.9 | 94% |
| 924 | alcohol-dependent patients | 1,427 | 1,547 | 18.9 | 92% |
| 925 | advanced esophageal cancer | 1,514 | 1,650 | 18.9 | 92% |
| 926 | afatinib | 1,813 | 1,998 | 18.9 | 91% |
| 927 | relapse-free survival (rfs) | 2,369 | 2,621 | 18.9 | 90% |
| 928 | suicide ideation | 3,372 | 3,671 | 18.9 | 92% |
| 929 | m184v | 1,025 | 1,063 | 18.9 | 96% |
| 930 | brafv600 | 2,704 | 2,982 | 18.9 | 91% |
| 931 | cancer pathogenesis | 3,178 | 3,475 | 18.9 | 91% |
| 932 | cancer diagnoses | 3,131 | 3,427 | 18.9 | 91% |
| 933 | antiretroviral (arv) | 1,634 | 1,791 | 18.9 | 91% |
| 934 | stroke management | 1,628 | 1,784 | 18.9 | 91% |
| 935 | severe maternal morbidity | 1,103 | 1,158 | 18.9 | 95% |
| 936 | stage iiic | 1,657 | 1,818 | 18.9 | 91% |
| 937 | adult congenital heart | 1,878 | 2,073 | 18.9 | 91% |
| 938 | advanced pancreatic cancer | 3,273 | 3,572 | 18.9 | 92% |
| 939 | malt lymphoma | 3,411 | 3,711 | 18.9 | 92% |
| 940 | pdac cells | 1,494 | 1,627 | 18.9 | 92% |
| 941 | plhiv | 2,307 | 2,554 | 18.9 | 90% |
| 942 | cancer resection | 3,638 | 3,937 | 18.9 | 92% |
| 943 | obesity-related disease | 1,293 | 1,388 | 18.9 | 93% |
| 944 | cancer cell invasion | 3,457 | 3,758 | 18.9 | 92% |
| 945 | downstaging | 2,816 | 3,102 | 18.9 | 91% |
| 946 | anti-her2 | 3,240 | 3,540 | 18.9 | 92% |
| 947 | pc-3 cells | 3,826 | 4,122 | 18.9 | 93% |
| 948 | simert | 1,992 | 2,204 | 18.9 | 90% |
| 949 | glargine | 2,980 | 3,274 | 18.9 | 91% |
| 950 | castration resistant | 1,346 | 1,452 | 18.9 | 93% |
| 951 | pediatric acute lymphoblastic leukemia | 1,212 | 1,291 | 18.9 | 94% |
| 952 | immune-checkpoint | 1,729 | 1,903 | 18.9 | 91% |
| 953 | mouse xenograft model | 3,801 | 4,098 | 18.9 | 93% |
| 954 | anti-mrsa | 1,216 | 1,296 | 18.9 | 94% |
| 955 | laryngeal squamous cell | 2,597 | 2,871 | 18.9 | 90% |
| 956 | cancer development and progression | 3,515 | 3,818 | 18.9 | 92% |
| 957 | rectal cancer surgery | 3,526 | 3,829 | 18.9 | 92% |
| 958 | diabetes medications | 1,106 | 1,163 | 18.9 | 95% |
| 959 | brca2 gene | 2,024 | 2,241 | 18.9 | 90% |
| 960 | raf inhibitor | 2,949 | 3,243 | 18.9 | 91% |
| 961 | interferon-free | 1,157 | 1,225 | 18.9 | 94% |
| 962 | bovine respiratory disease | 1,414 | 1,534 | 18.9 | 92% |
| 963 | hiv-1 viral load | 1,040 | 1,083 | 18.9 | 96% |
| 964 | chronic kidney diseases | 2,221 | 2,462 | 18.9 | 90% |
| 965 | micrometastasis | 2,654 | 2,933 | 18.9 | 90% |
| 966 | lung cancer screening | 3,548 | 3,852 | 18.9 | 92% |
| 967 | ovarian cancer cell lines | 3,312 | 3,616 | 18.9 | 92% |
| 968 | alk inhibitor | 1,477 | 1,609 | 18.9 | 92% |
| 969 | braf v600e mutation | 1,811 | 1,999 | 18.9 | 91% |
| 970 | hiv-associated neurocognitive disorder | 1,466 | 1,596 | 18.9 | 92% |
| 971 | community-acquired pneumonia (cap) | 4,496 | 4,759 | 18.9 | 94% |
| 972 | carboplatin and paclitaxel | 1,141 | 1,206 | 18.9 | 95% |
| 973 | severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection | 2,464 | 2,729 | 18.9 | 90% |
| 974 | sw620 | 2,428 | 2,690 | 18.9 | 90% |
| 975 | cancer symptom | 1,725 | 1,900 | 18.9 | 91% |
| 976 | tumor apoptosis | 1,299 | 1,397 | 18.9 | 93% |
| 977 | hcc risk | 1,390 | 1,506 | 18.9 | 92% |
| 978 | interstitial lung disease (ild) | 3,910 | 4,207 | 18.9 | 93% |
| 979 | multidrug-resistant tuberculosis | 3,478 | 3,784 | 18.9 | 92% |
| 980 | glargin | 3,013 | 3,312 | 18.9 | 91% |
| 981 | glycated haemoglobin (hba1c) | 1,844 | 2,038 | 18.9 | 90% |
| 982 | lung cancer screen | 3,563 | 3,869 | 18.9 | 92% |
| 983 | mcf-7 breast cancer cells | 3,915 | 4,213 | 18.9 | 93% |
| 984 | cardiovascular and cerebrovascular disease | 1,978 | 2,191 | 18.9 | 90% |
| 985 | non-small cell lung cancers | 1,905 | 2,108 | 18.9 | 90% |
| 986 | zikv infection | 2,070 | 2,295 | 18.9 | 90% |
| 987 | avian influenza virus (aiv) | 1,189 | 1,265 | 18.9 | 94% |
| 988 | epidermal growth factor receptor (egfr) mutations | 1,072 | 1,123 | 18.9 | 95% |
| 989 | germline brca | 1,236 | 1,322 | 18.9 | 93% |
| 990 | 5-year disease-free survival | 2,758 | 3,046 | 18.9 | 91% |
| 991 | breast cancer subtype | 3,791 | 4,094 | 18.9 | 93% |
| 992 | tumor-node-metastasis (tnm) | 1,145 | 1,212 | 18.9 | 94% |
| 993 | laboratory-confirmed influenza | 994 | 1,028 | 18.9 | 97% |
| 994 | undetectable viral load | 1,430 | 1,555 | 18.9 | 92% |
| 995 | high-fat diet-induced obesity | 1,061 | 1,110 | 18.9 | 96% |
| 996 | lung cancer diagnosis | 1,683 | 1,853 | 18.9 | 91% |
| 997 | cardiovascular disease prevention | 2,177 | 2,416 | 18.9 | 90% |
| 998 | breast cancer gene | 3,069 | 3,372 | 18.9 | 91% |
| 999 | asthma guidelines | 1,056 | 1,104 | 18.9 | 96% |
| 1000 | asthma control questionnaire | 966 | 994 | 18.9 | 97% |